cell carcinoma accounts for 80% of KC in transplant recipients and has higher rates of recurrence and metastasis with 26-to 52-fold higher standardized mortality compared with immunocompetent patients. [13] [14] [15] [16] Given the substantial resources committed to the organ procurement, transplantation, and maintenance stages of transplant care, preventive measures are critical to ensure long-term wellbeing and reduce the burden of KC in this high-risk population.
National and international guidelines for posttransplant care recommend annual dermatology assessments to screen for skin cancer and educate patients about sun protection. 17 However, the level of evidence for this recommendation is rated as low by guideline developers due to a lack of efficacy data in terms of KCrelated outcomes. The paucity of evidence may at least partly explain why adherence to regular skin examination has historically been low. [18] [19] [20] [21] [22] By applying a validated insurance claims-based algorithm, 23 we used population-based, administrative health databases to evaluate the association between annual dermatology assessment and rates of KC-related morbidity and mortality among solid organ transplant recipients in Ontario, Canada from 1994 to 2013. We also aimed to identify factors associated with advanced KC and with becoming upto-date with annual dermatology assessment. To identify transplant recipients, we used the Canadian Organ Replacement Register (CORR), a national database with >98% completeness. 24 CORR data were securely linked to other administrative health databases using unique encoded identifiers and analyzed at ICES.
| ME THODS

| Exposure definition
Using fee-for-service physician claims submitted to the Ontario Health Insurance Plan (OHIP), we identified all outpatient consultations and follow-up assessments by a dermatologist. OHIP is the lone insurer of medically necessary care for Ontario residents (population > 13.5 million). We measured adherence to annual dermatology assessments starting at 6 months posttransplant. For each patient and for each day of follow-up, we calculated the percentage of time that the patient had spent in adherence prior to that day. This was defined as the amount of time in adherence divided by the total preceding observation time for each patient ( Figure S1 ). After each dermatology assessment, patients were considered to be in adherence for 13 months, after which they were considered nonadherent until their next dermatology assessment. The use of a 13-month interval (vs. 12 months) to define adherence provided an extra month of flexibility for physician scheduling practices. Importantly, the percentage of time in adherence was treated as a time-varying exposure, meaning that the value was updated daily to reflect adherence up to that time point.
| Outcome definitions
Since the Ontario Cancer Registry does not capture KC, we used a validated OHIP claims-based algorithm (83-85% sensitivity, 93-99% specificity) 23 to ascertain incident KC diagnosed after 6 months posttransplant. As surgical excision constitutes the primary treatment for KC and nodal metastasis, we defined a high level of KC-related morbidity as having one of the following surgical procedures performed within 3 months after a KC diagnosis date:
(1) surgical excision with local flap reconstruction for a tumor diameter greater than 2 cm, which is a major prognostic factor used in KC staging; [25] [26] [27] [28] [29] (2) complex reconstruction consisting of free flaps, major pedicled flaps, large split-thickness or facial full-thickness skin grafts, or cartilage grafts; and (3) lymphadenectomy. These surgical procedures were identified using specific procedure codes in OHIP claims (Table S1 ) and hospital records from the Canadian Institute for Health Information. We classified a KC as fatal if the death certificate listed the squamous or basal cell carcinoma as a primary or secondary cause of death in the Ontario Registrar General Death database. The date of diagnosis for the first advanced (highly-morbid or fatal) KC was defined by the earliest occurrence of the following hierarchical events: (1) highly-morbid KC;
(2) most recent KC diagnosis preceding a KC-related death; or (3)
KC-related death. 
| Potential risk factors and confounders
| Statistical analysis
We fit a multivariable cause-specific hazard model to estimate the association between adherence to annual dermatology assessment and the rate of first advanced (highly morbid or fatal) KC, while accounting for the competing risks of death unrelated to KC or return to dialysis after kidney graft failure. 32, 33 We did not consider nonadvanced KC to be an exit criterion or covariate because it occurs along the causal pathway of the exposure and outcome. The percentage of preceding observation time spent in adherence (<25%, 25
to <50%, 50 to <75%, ≥75%) was modelled as the main time-varying exposure. To account for whether adherence was more proximate or remote in time, we also included current adherence status in the model as a binary time-varying covariate that was updated daily and defined by having had a dermatology assessment in the prior 13 months ( Figure S1 ). The model included the potential risk factors and confounders listed above. We treated rurality of residence, income quintile, precancerous skin lesions, subsequent transplantation, outpatient physician (non-dermatologist) visits in the prior 12 months, and hospitalization in the prior 3 months as time-varying covariates during the posttransplant observation period. To evaluate the impact of missing race data, we conducted two sensitivity analyses: one restricted to patients of known white race and another imputing white race for patients with missing race data.
We estimated the cumulative incidence of advanced KC at 5 years using the cumulative incidence function (instead of the complement of the Kaplan-Meier estimator) to properly account for competing risks.
32
To identify factors associated with becoming up-to-date with annual dermatology assessments when a patient was currently nonadherent, we fit an extended multivariable Cox regression model for recurrent events (Andersen-Gill model) based on a counting process data structure under a three-state transitional model. 34 The three states consisted of (1) being non-adherent, (2) being adherent, and (3) having any absorbing event (exit criterion consisting of any KC, melanoma, death, and return to dialysis after kidney graft loss). A patient could transition back and forth between being adherent (state 1) and non-adherent (state 2) until an absorbing state was reached.
Since we aimed to examine dermatology assessment as a preventive measure prior to developing posttransplant skin cancer, any KC or melanoma was considered to be an absorbing event for this analysis.
The variance estimation was computed using a robust sandwichtype variance estimator.
The advantage of this approach is that it takes into account the pattern of time spent in non-adherence. Since a patient could have multiple episodes of being non-adherent, the Andersen-Gill model included discontinuous risk intervals during which non-adherent patients were "at risk" for becoming adherent. Each risk interval started when the patient became non-adherent (13 months after the last dermatology visit) and ended with the next dermatology visit or absorbing event (eg, Periods A and C in Figure S1 ). Patients who remained continuously adherent throughout the observation period had no risk intervals during which they were non-adherent and thus at risk of becoming adherent, and were therefore excluded from the model. The same potential risk factors and confounders listed above
were included in the model. Because the Markov assumption was violated (ie, the past adherence level had a statistically significant impact on the current adherence status), we also included the proportion of time spent in adherence as a time-varying covariate.
Statistical analyses were performed using SAS (Version 9.4). We calculated 95% confidence intervals and used a two-sided significance level of 0.05.
| RE SULTS
| Cohort characteristics
We identified The median age at transplant was 51 years (interquartile range, IQR 41-59) ( Table 1) . Two-thirds were male and over half were of white race. Patients were evenly distributed across income quintiles and over a tenth resided in rural areas at the time of transplant. Four percent (N = 453) of patients had a KC or melanoma prior to transplant.
Kidney transplants accounted for 62% of the cohort, followed by liver (24%), lung (8%), and heart (7%) transplants.
| Adherence and keratinocyte carcinoma outcomes
A total of 10 183 transplant recipients were observed for a me- Only 4555 (44.7%) patients were ever assessed by a dermatologist after transplant (Table 1) , and only 212 (2.1%) were fully adherent to annual dermatology assessments during the entire posttransplant observation period. The proportion of time spent in adherence did not vary substantially with time since transplant (median 0% during 0.5-3 years, 3-6 years, 6-9 years; median 11% beyond 9 years posttransplant). In a sensitivity analysis, similarly low adherence (2.9% fully adherent) was observed if an extended 18-month interval between dermatology assessments was used to define adherence.
The first advanced (highly-morbid or fatal) KC was identified in 497 (4.9%) patients (Table 2) had similar rates (Table 3) . These effects were observed after adjustment for current adherence status (aHR 1.12, 95% CI 0.87-1.45) and established skin cancer risk factors (Table 3 ). The unadjusted and adjusted hazard ratios for adherence were in opposite directions, indicating strong confounding by covariates included for adjustment in the multivariable model. Pretransplant skin cancer and posttransplant actinic keratosis or in situ skin carcinoma were the strongest confounders (data not shown).
The results did not change substantially in sensitivity analyses imputing unknown race as white or restricting to patients of known white race (Table S2) . In an exploratory test for interaction, the association between time in adherence (≥75% vs. <75%) and the rate of advanced KC differed significantly between current adherers (aHR 0.57, 95% CI 0.39-0.82) compared with current non-adherers (aHR 1.13, 95% CI 0.63-2.03) (P = .046 for interaction).
Patients with white race (vs. non-white race) or age greater than 50 years (vs. 18-35 years) at transplant had a five-fold increased rate of advanced KC ( (Table 3 ).
| Factors associated with adherence
A total of 9886 transplant recipients with a median observation time of 5.19 years (IQR 2.68-9.01) were included in the analysis of factors associated with becoming up-to-date with adherence ( Figure 1 ).
These patients exited the observation period due to the end of the study period (57.5%, N = 5688), death (17.5%, N = 1729), KC (15.3%, N = 1508), kidney graft failure (7.9%, N = 785), outmigration (1.6%, N = 157), and melanoma (0.19%, N = 19).
Among skin cancer risk factors, a prior diagnosis of precancerous or cancerous skin lesions was the strongest independent predictor of becoming up-to-date with annual dermatology visits, with adjusted hazard ratios ranging from 1.91 to 2.61 ( Other factors associated with higher adherence rates included single organ transplant (vs. multiorgan), urban residence, higher income, and more recent transplant years (Table 4 ).
| D ISCUSS I ON
Advances in transplantation have led to prolonged graft survival and increasing numbers of transplants performed annually. Given the limited supply of donor organs and the considerable efforts to ensure successful transplantation, it is incumbent upon healthcare providers and organ recipients to maximize the long-term benefits and reduce the complications of chronic immunosuppression. As the most common posttransplant malignancy, KC warrants particular attention in terms of prevention. Annual dermatology assessment provides the opportunity for skin cancer screening, chemoprevention, and education to promote earlier diagnosis and treatment as well as sun protective behaviors, but evidence of benefit in terms of improved outcomes has been lacking.
In a population-based cohort of solid organ transplant recipients, we found that higher adherence was associated with a 34% reduction in advanced KC. A linear dose-response relationship was not seen, as the benefit was only found with the highest quartile of
adherence. An exploratory analysis also revealed that the rate reduction was greatest among patients who were currently adherent, suggesting that it is important to promote both consistent cumulative adherence over time and recent adherence among transplant recipients. Although we used an annual assessment interval to define adherence, as recommended by transplant care guidelines, 17 certain subsets of transplant recipients who are at particularly high risk of advanced skin cancer may benefit from more frequent dermatology assessments. The strongest risk factors for advanced KC in our cohort were white race and older age at the time of transplant, with a continual increase in risk from the age of 36 years onwards. A previous cohort study found that similar factors were associated with increased KC-specific mortality. 35 Given that the proportion of patients transplanted at an age of 60 years or older has increased by 50% from 2005 to 2014 in the United States, 36 Canada, 37 and the United Kingdom, 38 we can expect future growth in the burden of advanced KC in this population. We also showed that patients with prior precancerous or cancerous skin lesions, subsequent transplantation, and lung graft were at higher risk. 
TA B L E 1 Cohort characteristics (N = 10 183)
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Adherence levels in our cohort were very low throughout the posttransplant follow-up period across all subsets of transplant recipients, including those with the highest risk of advanced skin cancer. Our estimates of adherence levels based on health insurance claims are lower and more reliable than previous estimates based on self-reported survey data in the United Kingdom, United States, France, and Denmark. [18] [19] [20] [21] [22] A major reason for non-adherence is the failure of transplant centers to routinely refer patients for annual dermatology assessment. 19, 21, 22 We noted substantial variation in adherence between the six adult transplant centers in Ontario, which suggests that local practices play an important role in ensuring adherence.
Previously reported barriers to referral include a perceived lack of evidence supporting the efficacy of routine screening and the difficulty in obtaining a dermatology appointment. 22 We found that patients residing in urban communities had higher rates of becoming adherent, reinforcing the importance of accessibility to a dermatologist.
There may also be a lack of patient awareness about skin cancer risk and the importance of dermatology assessment after transplant. 18 To help address these barriers, our study provides evidence of improved KC-related outcomes associated with adherence to annual dermatology assessment. Better skin cancer awareness and accessibility to dermatologists can be achieved in part through specialized transplant dermatology clinics integrated within transplant centers as well as international organizations that provide patient education materials and a forum to advance common clinical and research goals. 12, [39] [40] [41] [42] [43] Transplant centers may also find it useful to implement a system that ensures regular referrals for dermatology assessment as part of routine practice. 39 Our study has limitations. First, observational associations cannot be confirmed as causal. A "healthy adherer" effect due to unmeasured confounders cannot be ruled out. However, we adjusted for important known confounders, including indicators of sensitivity or past exposure to ultraviolet radiation such as race and pretransplant skin cancers. Second, race data were missing for 23% of patients.
However, sensitivity analyses involving imputation or restriction did not substantially alter the results. Third, it was not possible to determine, based on health insurance claims, whether a given dermatology assessment included a full-body skin examination or education about sun protection and skin self-examination. This means that screening and education rates may be overestimated in our study, and the strength of association between adherence and improved KC-related outcomes may be underestimated. However, the vast majority of dermatologists report performing full-body skin cancer screening in all high-risk patients. 44 Similarly, we could not capture any skin examinations or education performed by nurses or non-dermatologist TA B L E 2 Incidence of first advanced keratinocyte carcinoma after transplant, stratified by level of adherence to annual dermatology assessment TA B L E 3 Association between adherence to annual dermatology visits and rate of advanced keratinocyte carcinoma, adjusted for potential confounders (N = 10 183) physicians, leading to further potential underestimation of the association between adherence and advanced KC. Fourth, due to the exclusion of KC from major cancer registries in North America, we identified KC using a validated OHIP claims-based algorithm. 23 OHIP diagnosis codes do not distinguish squamous from basal cell carcinoma, which differ in their metastatic potential. However squamous cell carcinoma represents 80% of posttransplant skin cancers. 45 Fifth, when identifying factors associated with the rate of becoming adherent, we selected an analytic approach that allowed us to account for the pattern of adherence, varying lengths of follow-up, competing risks, and time-varying covariates. Although our analysis excluded patients who were 100% adherent during the follow-up period (see Section 2), this represented a small subset (2.1%) of our cohort. A multivariable logistic regression analysis including all patients to identify factors associated with being 100% adherent found similar results to our main analysis (data not shown), but does not allow for the advantages of our main approach listed above.
Our population-based study provides evidence supporting the importance of annual dermatology assessment as part of posttransplant care. Further efforts to define the optimal frequency of assessment through risk stratification and to address barriers to dermatology care with the goal of improving adherence levels may help promote the long-term health of transplant survivors.
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